背景:尽管人们越来越认识到肥胖危机,其利率继续上升。目前的一线疗法,比如饮食变化,能量限制,和身体活动,通常会遇到较差的依从性。新的营养干预措施可以解决肥胖的根本原因,包括线粒体功能障碍,并促进减肥。
目的:本研究的目的是调查在12周内为促进线粒体功能和代谢健康结果而设计的多成分营养补充剂的效果。
方法:55名超重和/或肥胖参与者(年龄(平均值±SEM):26±1;体重指数(BMI)(kg/m2):30.5±0.6)完成了这一双盲,安慰剂对照临床试验。参与者被随机分配到每天12周的多成分补充剂(MIS;n=28;含有50毫克毛喉素,500毫克绿咖啡豆提取物,500毫克绿茶提取物,500毫克甜菜根提取物,400毫克α-硫辛酸,200IU维生素E,和200毫克辅酶Q10)或对照安慰剂(PLA,n=27;含有微晶纤维素)外观匹配。共同的主要结果是体重和脂肪量(kg)的变化。次要结果包括其他身体成分测量,肥胖的血浆标志物,脂肪肝疾病生物标志物,静息能量代谢,血压,物理性能,和生活质量。通过ANCOVA检查MIS和PLA之间的干预后差异,并针对各自的干预前变量进行了调整。
结果:调整干预前数据后,干预后PLA和MIS治疗组之间的体重(p<0.001)和脂肪量(p<0.001)存在显着差异。MIS干预后体重和脂肪量显著降低。在临床生物化学标志物中发现了经基线校正的干预后显著差异(AST,p=0.017;ALT,p=0.008),分子代谢(GDF15,p=0.028),MIS中与细胞外囊泡相关的miRNA种类miR-122和miR-34a(p<0.05)。
结论:在补充MIS12周后,体重和身体成分显著改善,伴随着肝脏健康和代谢的分子标志物的改善。
BACKGROUND: Despite the growing recognition of the obesity crisis, its rates continue to rise. The current first-line therapies, such as dietary changes, energy restriction, and physical activity, are typically met with poor adherence. Novel nutritional interventions can address the root causes of obesity, including mitochondrial dysfunction, and facilitate weight loss.
OBJECTIVE: The objective of this
study was to investigate the effects of a multi-ingredient nutritional supplement designed to facilitate mitochondrial function and metabolic health outcomes over a 12 wk period.
METHODS: Fifty-five overweight and/or obese participants (age (mean ± SEM): 26 ± 1; body mass index (BMI) (kg/m2): 30.5 ± 0.6) completed this double-blind, placebo-controlled clinical
trial. Participants were randomized to 12 wks of daily consumption of multi-ingredient supplement (MIS; n = 28; containing 50 mg forskolin, 500 mg green coffee bean extract, 500 mg green tea extract, 500 mg beet root extract, 400 mg α-lipoic acid, 200 IU vitamin E, and 200 mg CoQ10) or control placebo (PLA, n = 27; containing microcrystalline cellulose) matched in appearance. The co-primary outcomes were bodyweight and fat mass (kg) changes. The secondary outcomes included other body composition measures, plasma markers of obesity, fatty liver disease biomarkers, resting energy metabolism, blood pressure, physical performance, and quality of life. The post-intervention differences between MIS and PLA were examined via ANCOVA which was adjusted for the respective pre-intervention variables.
RESULTS: After adjustment for pre-intervention data, there was a significant difference in weight (p < 0.001) and fat mass (p < 0.001) post-intervention between the PLA and MIS treatment arms. Post-intervention weight and fat mass were significantly lower in MIS. Significant post-intervention differences corrected for baseline were found in markers of clinical biochemistry (AST, p = 0.017; ALT, p = 0.008), molecular metabolism (GDF15, p = 0.028), and extracellular vesicle-associated miRNA species miR-122 and miR-34a in MIS (p < 0.05).
CONCLUSIONS: Following the 12 wks of MIS supplementation, weight and body composition significantly improved, concomitant with improvements in molecular markers of liver health and metabolism.